Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
BioNxt Solutions ( (TSE:BNXT) ) has provided an announcement.
BioNxt Solutions Inc. announced an amendment to its previously issued unsecured convertible debenture, extending its maturity date by one year to December 7, 2025. The company will issue common shares at a market price of $0.285 to settle accrued interest, resulting in the issuance of 1,459,649 shares. This strategic move allows BioNxt to manage its financial obligations and continue focusing on its operational goals in the European medical market.
More about BioNxt Solutions
BioNxt Solutions Inc. is a bioscience accelerator specializing in next-generation drug formulations and delivery systems, diagnostic screening tests, and the production and evaluation of new active pharmaceuticals. The company operates in North America and Europe, with a focus on regulatory approval and commercialization of medical products in European markets.
YTD Price Performance: 5.71%
Average Trading Volume: 11,278
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $30.76M
See more insights into BNXT stock on TipRanks’ Stock Analysis page.
